Q5151 HCPCS code: Injection, eculizumab-aagh (epysqli), biosimilar, 2 mg
Q5151 is the HCPCS Level II code for injection, eculizumab-aagh (epysqli), biosimilar, 2 mg. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 600 per day on DME suppliers.
Code details
| Field | Value |
|---|---|
| Section | Q codes — Temporary codes |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2025-04-01 |
| Last action effective | 2025-04-01 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| DME suppliers | 600 | Prescribing Information |
| outpatient hospital claims | 600 | Prescribing Information |
| practitioner claims | 600 | Prescribing Information |
Medicare policy articles for this code
- A54548: Billing and Coding: Eculizumab, and Biosimilars: EPYSQLI®-eculizumab-aagh, and BKEMV™-eculizumab-aeeb (Wellpoint Federal (MAC - Part A, MAC - Part B))
Covered diagnoses (18 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| D59.31 | Infection-associated hemolytic-uremic syndrome | 1 |
| D59.32 | Hereditary hemolytic-uremic syndrome | 1 |
| D59.39 | Other hemolytic-uremic syndrome | 1 |
| D59.5 | Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli] | 1 |
| G36.0 | Neuromyelitis optica [Devic] | 1 |
| G70.00 | Myasthenia gravis without (acute) exacerbation | 1 |
| G70.01 | Myasthenia gravis with (acute) exacerbation | 1 |
| N00.6 | Acute nephritic syndrome with dense deposit disease | 1 |
| N00.B1 | Acute nephritic syndrome with idiopathic immune membranoproliferative glomerulonephritis (IC-MPGN) | 1 |
| N00.B2 | Acute nephritic syndrome with secondary immune complex membranoproliferative glomerulonephritis (IC-MPGN) | 1 |
Showing 10 of 18. The full list, non-covered diagnoses and CSV export are in Caduvo.
What changed for Q5151
- April 2025: Code appears in this HCPCS release
- 2025-04-01: Q5151 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code Q5151?
Q5151 is the HCPCS Level II code for injection, eculizumab-aagh (epysqli), biosimilar, 2 mg. Short descriptor: "Inj, eculizumab-aagh, 2 mg".
Does Medicare cover Q5151?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Which diagnoses support coverage for Q5151?
Medicare policy articles that cite Q5151 list 18 covered ICD-10-CM diagnosis codes across 1 article. The most cited include D59.31 (Infection-associated hemolytic-uremic syndrome), D59.32 (Hereditary hemolytic-uremic syndrome), D59.39 (Other hemolytic-uremic syndrome). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of Q5151 can be billed per day?
600 on DME suppliers; 600 on outpatient hospital claims; 600 on practitioner claims (NCCI medically unlikely edits).
Related Q51 codes
- Q5100 — Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg
- Q5101 — Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram
- Q5102 — Injection, infliximab, biosimilar, 10 mg
- Q5103 — Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg
- Q5104 — Injection, infliximab-abda, biosimilar, (renflexis), 10 mg
- Q5105 — Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units
- Q5106 — Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units
- Q5107 — Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
- Q5108 — Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
- Q5109 — Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg
- Q5110 — Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
- Q5111 — Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under Q5151
- Watch Q5151 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for Q5151
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.